This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Río, J. Articles by Montalban, X. Search for Related Content PubMed PubMed Citation Articles by Río, J. Articles by Montalban, X. Social Bookmarking                   What's this?

Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain, jrio{at}vhebron.net

Joana Porcel

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Nieves Téllez

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Angela Sánchez-Betancourt

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

M ar Tintoré

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

M Jesús Arévalo

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Carlos Nos

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Xavier Montalban

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Background: Awareness of the factors influencing discontinuation of immunomodulatory drugs (IMD) treatment in multiple sclerosis (MS) can help to find approaches to patient management with the aim of establishing more specific indications and also attaining more optimal patient selection in future clinical trials. Objective: To identify the causes that influence adhesion to IMD therapy within the clinical practice in a large cohort of patients with MS. Patients and methods: We have studied all MS patients who have initiated IMD in our hospital. All patients took part in training sessions where treatment expectations and side effects were explained and they received training in the administration technique. Reasons for stopping therapy were recorded during follow-up. Results: We studied 632 MS patients (mean follow-up was 47.1 (28.7) months). At the time of analysis, 107/632 patients (17%) were no longer receiving IMD. Almost half of the patients who stopped IMD (52/107) did so within the first two years on therapy. Fifty-six patients stopped IMD because of lack of efficacy. Only 27 patients (4.3%) discontinued treatment for reasons other than inefficacy or side effects. The proportion of patients with secondary progressive MS that stopped IMD therapy was 30%, while only 13.5% of the patients with relapsing—remitting MS stopped therapy (P= 0.0001). Expanded Disability Status Scale (EDSS) score at entry was the main factor that predicted interruption of therapy. Conclusions: The proportion of patients interrupting IMD in our centre is low, possibly due to individualized care. Higher EDSS, mainly in the first two years of treatment, is the main factor related with interruption. Close follow-up of these patients would be useful in avoiding early discontinuation of therapy.

Key Words: interferon • multiple sclerosis • immunomodulatory • adherence • response • efficacy

Multiple Sclerosis, Vol. 11, No. 3, 306-309 (2005)
DOI: 10.1191/1352458505ms1173oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J Rio, J Castillo, A Rovira, M Tintore, J Sastre-Garriga, A Horga, C Nos, M Comabella, X Aymerich, and X Montalban Measures in the first year of therapy predict the response to interferon {beta} in MS Multiple Sclerosis, July 1, 2009; 15(7): 848 - 853. [Abstract] [PDF]

				P Coyle, B Arnason, B Hurwitz, and F Lublin Optimizing Outcomes in Multiple Sclerosis - A Consensus Initiative Multiple Sclerosis, February 1, 2009; 15(2_suppl): S5 - S35. [Abstract] [PDF]

				A Gajofatto, P Bacchetti, B Grimes, A High, and E Waubant Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Multiple Sclerosis, January 1, 2009; 15(1): 50 - 58. [Abstract] [PDF]

				A. P. Ross Strategies for optimal disease management, adherence, and outcomes in multiple sclerosis patients. Neurology, December 9, 2008; 71(24 Suppl 3): S1 - S2. [Full Text] [PDF]

				A. P. Ross Tolerability, adherence, and patient outcomes Neurology, December 9, 2008; 71(24_suppl_3): S21 - S23. [Abstract] [Full Text] [PDF]

				P. Rieckmann, A. Traboulsee, V. Devonshire, and J. Oger Review: Escalating immunotherapy of multiple sclerosis Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 181 - 192. [Abstract] [PDF]

				S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]

				L.I. Iezzoni, L.H. Ngo, and R.P. Kinkel Working-age persons with multiple sclerosis and access to disease-modifying medications Multiple Sclerosis, January 1, 2008; 14(1): 112 - 122. [Abstract] [PDF]